334 related articles for article (PubMed ID: 21504247)
1. Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.
Keating GM
Drugs; 2011 Apr; 71(6):679-707. PubMed ID: 21504247
[TBL] [Abstract][Full Text] [Related]
2. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
Dunn CJ; Goa KL
Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
[TBL] [Abstract][Full Text] [Related]
3. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
4. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
6. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
Seymour AM; de Campos E; Thatcher N; De Greve J; Cunningham D; Howell A; Tueni E; Bron DG; Steward WP; Berdel WE
Eur J Cancer; 1995 Dec; 31A(13-14):2157-63. PubMed ID: 8652235
[TBL] [Abstract][Full Text] [Related]
7. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
[TBL] [Abstract][Full Text] [Related]
9. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial.
Linch DC; Milligan DW; Winfield DA; Kelsey SM; Johnson SA; Littlewood TJ; Smith GM; Hutchinson RM; Goldstone AH; Fielding AK; Vaughan Hudson G
Br J Haematol; 1997 Dec; 99(4):933-8. PubMed ID: 9432046
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of available clinical evidence - filgrastim compared with lenograstim.
Sourgens H; Lefrère F
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):510-8. PubMed ID: 21781651
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects.
Akizuki S; Mizorogi F; Inoue T; Sudo K; Ohnishi A
Bone Marrow Transplant; 2000 Nov; 26(9):939-46. PubMed ID: 11100272
[TBL] [Abstract][Full Text] [Related]
12. Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.
Gunzer K; Clarisse B; Lheureux S; Delcambre C; Joly F
Expert Opin Biol Ther; 2010 Apr; 10(4):615-30. PubMed ID: 20218922
[TBL] [Abstract][Full Text] [Related]
13. A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Takeyama K; Ogura M; Morishima Y; Kasai M; Kiyama Y; Ohnishi K; Mitsuya H; Kawano F; Masaki Y; Sasaki T; Chou T; Yokozawa T; Tobinai K;
Jpn J Clin Oncol; 2003 Feb; 33(2):78-85. PubMed ID: 12629058
[TBL] [Abstract][Full Text] [Related]
14. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
[TBL] [Abstract][Full Text] [Related]
16. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.
Frampton JE; Lee CR; Faulds D
Drugs; 1994 Nov; 48(5):731-60. PubMed ID: 7530630
[TBL] [Abstract][Full Text] [Related]
17. Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy.
Anderlini P; Champlin R
Drugs; 2002; 62 Suppl 1():79-88. PubMed ID: 12479596
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors.
Hölig K; Kramer M; Kroschinsky F; Bornhäuser M; Mengling T; Schmidt AH; Rutt C; Ehninger G
Blood; 2009 Oct; 114(18):3757-63. PubMed ID: 19666868
[TBL] [Abstract][Full Text] [Related]
19. Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).
Jung EH; Byun JM; Shin DY; Do YR; Jo JC; Lee SM; Yoon SS
Cancer Med; 2023 Apr; 12(8):9186-9193. PubMed ID: 36951655
[TBL] [Abstract][Full Text] [Related]
20. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients.
Lefrère F; Bernard M; Audat F; Cavazzana-Calvo M; Belanger C; Hermine O; Arnulf B; Buzyn A; Varet B
Leuk Lymphoma; 1999 Nov; 35(5-6):501-5. PubMed ID: 10609787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
